To read the full story, subscribe or sign in.

Yufan inks deal with Abound to develop antibodies directing CAR T cells against cancer targets

Oct. 5, 2020

HONG KONG – Xi’an, China-based Yufan Biotechnologies Co. Ltd. has partnered with Pittsburgh-based Abound Bio Inc. to discover and develop antibodies directing CAR T cells against cancer targets.

BioWorld Deals and M&A Cancer CAR T China

Free access to BioWorld coronavirus articles

BioWorld

The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note...

Today's news in brief

BioWorld

BioWorld briefs for Aug. 16, 2022.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Aug. 16, 2022.

Whole body cellular function recovery in pigs after death

Science

A new system for restoring cell function and tissues in mammals after death could expand the availability of organs for transplantation. The research also opens...

Siga leads monkeypox antiviral research, amid lack of interest from big pharma

BioWorld

After declarations from the World Health Organization and the U.S. government that monkeypox is a public health emergency, attention is turning to the pharma...

Upgrade your daily dose of biopharma and medtech news

Yufan inks deal with Abound to develop antibodies directing CAR T cells against cancer targets